For companies developing new therapeutics, diagnostics, medical technologies, or digital health solutions, success depends on more than a strong product. It requires international validation, specialized capital, clinical and regulatory expertise, and trusted routes into healthcare systems. This is why Biovia is working to support a more connected, internationally visible ecosystem — one that helps companies scale beyond regional and national boundaries.
The Limits of a Local Market
Building a company in biotech or healthtech is fundamentally different from launching a consumer software product. The route to market is slower, more expensive, and more heavily regulated. Startups may need to navigate clinical trials, hospital procurement, reimbursement pathways, data access, regulatory approval, and long validation cycles before they can reach patients or healthcare providers at scale.
That makes it difficult for companies to grow if they think too locally. Belgium is a strong innovation ecosystem, but it is also a small and complex market. For many companies, the home market can be an important place to build, validate, and connect, but it cannot be the only horizon.
“Health innovation companies need to think internationally from the very beginning.” – Rita Prota
“Health innovation companies need to think internationally from the very beginning,” says Rita Prota, Business Partnerships & Programs Lead at Biovia. “Belgium is an excellent place to develop and test innovation, but the market is too small to be the end goal. If we want companies to grow, attract capital, and reach patients, we need to prepare them for scale from day one.”
This is particularly important in sectors where capital intensity is high. A biotech company cannot simply bootstrap its way through a clinical trial. A healthtech company may have a strong solution, but still struggle to secure hospital adoption without evidence, reimbursement clarity, and trusted validation. In both cases, international investors and partners can play a decisive role.
Why International Validation Matters
For companies in complex science-driven sectors, international capital brings more than money. It can also provide credibility.
Investors, strategic partners, and potential acquirers often face a significant information gap when assessing early-stage technologies. Few outside experts can fully evaluate the scientific, regulatory, and commercial potential of a new therapeutic, diagnostic platform, or health technology solution on their own. As a result, the market relies heavily on signals.
“International investors do not only bring capital.” – Rita Prota
Backing from respected international investors can therefore act as a form of validation. It tells the wider market that a company has been assessed by experienced actors who understand the field, the risk, and the potential upside. That signal can help companies attract further investment, recruit talent, build partnerships, and open doors in new markets.
“International investors do not only bring capital,” says Prota. “They bring networks, credibility, and a broader view of what it takes to compete globally. For young companies, that external validation can be extremely powerful — especially when the technology is complex and the path to market is long.”
From Fragmentation to Critical Mass
Belgium has many of the ingredients that companies need to succeed: strong universities, research institutes, hospitals, startups, SMEs, investors, and established life sciences companies. Yet the same ecosystem can also be difficult to navigate.
For international investors or partners, regional fragmentation can make it harder to understand where to go, who to speak to, and how to access the right opportunities. For startups, it can mean navigating multiple programs, pilots, funding structures, hospital networks, and support mechanisms without a clear route to scale.
“When we go abroad, we should not present ourselves as isolated pockets of innovation.” – Rita Prota
The challenge is not that regional strengths should disappear. Local ecosystems are often where companies find their first partners, customers, mentors, and champions. The issue is that these strengths need to be connected and presented internationally as part of a larger, more mature whole.
“Regional ecosystems are incredibly valuable, but we have to be careful not to let fragmentation weaken our global position,” says Prota. “When we go abroad, we should not present ourselves as isolated pockets of innovation. We should show the world that Belgium, and Europe more broadly, can act with focus, quality, and critical mass.”
For Biovia, this is a central part of the cluster’s role: helping to connect actors across the ecosystem, reduce barriers to collaboration, and create stronger pathways between innovation, validation, capital, and market access.
Building the Infrastructure for Scale
This thinking is reflected in Biovia’s development of an Expertise Centre for Market Acceleration, designed to address the structural barriers that prevent promising biotech and healthtech companies from scaling successfully.
In many cases, the main obstacles are not technological. Companies may have a strong scientific foundation or a validated solution, but still struggle with regulatory complexity, clinical adoption, access to health data, business model development, or first customer acquisition. These challenges require coordination between industry, healthcare providers, policymakers, investors, and support organizations.
“Technology is rarely the only bottleneck.” – Rita Prota
“Technology is rarely the only bottleneck,” says Prota. “Many companies know what they are building, but they need support in understanding how that innovation will be adopted, reimbursed, regulated, financed, and scaled. Market acceleration is about connecting those pieces much earlier in the journey.”
Alongside this longer-term roadmap, Biovia is also rolling out practical initiatives to support companies now, including educational sessions on regulatory compliance, business model development, and investor readiness.
Taking the Ecosystem Abroad
International visibility is another key part of the strategy. In September 2026, Biovia will partner with Flanders Investment & Trade, VIB, and the Solvay Alumni Association on a US mission to Boston, giving participating companies and ecosystem actors the opportunity to connect with American investors, strategic partners, and innovation leaders.
The value of such missions lies not only in individual meetings, but also in collective positioning. By traveling as a coordinated delegation, Belgian companies can present themselves as part of a broader, investment-ready ecosystem rather than as isolated ventures looking for attention in a crowded market.
Biovia is also helping to bring international investors to Belgium. The HealthTech Investor Summit, taking place in Bruges from November 30 to December 2, 2026, will gather selected pitching companies from across Europe alongside international investors. By focusing on cross-border deal flow and high-quality matchmaking, the summit is designed to reduce the friction of international networking and help companies build relationships that could otherwise take months to develop.
Find out more about Biovia’s internationalization and market access events!
Belgium’s life sciences ecosystem has the talent, science, and entrepreneurial energy to build companies with global relevance. The next step is ensuring those strengths are connected, visible, and ready for scale.
“If we connect our strengths and act internationally,” concludes Prota, “Belgium can be much more than a strong local ecosystem — it can be a launchpad for global health innovation.”